866-997-4948(US-Canada Toll Free)

Peanut Allergy - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 84 Pages

Peanut Allergy - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides an overview of the Peanut Allergy (Immunology) pipeline landscape.

Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms can include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peanut Allergy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peanut Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peanut Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Peanut Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 8 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 1 and 1 molecules, respectively.

Peanut Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peanut Allergy (Immunology).
- The pipeline guide reviews pipeline therapeutics for Peanut Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peanut Allergy (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peanut Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peanut Allergy (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peanut Allergy (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peanut Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peanut Allergy - Overview
Peanut Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Peanut Allergy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peanut Allergy - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
Aimmune Therapeutics Inc
Alfacyte Ltd
Allergy Therapeutics Plc
AnaptysBio Inc
ASIT Biotech SA
Astellas Pharma Inc
BioLingus AG
DBV Technologies SA
HAL Allergy BV
Intrommune Therapeutics
Sanofi
Peanut Allergy - Drug Profiles
aldesleukin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANB-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANN-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-0892 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBV-712 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Inhibit CYP11A1 for Peanut Allergy and Asthma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HALMPE-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PER-1080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pnut-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polyvac Peanut - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-439794 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCV-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine 2 for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Peanut Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTC-064 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peanut Allergy - Dormant Projects
Peanut Allergy - Discontinued Products
Peanut Allergy - Product Development Milestones
Featured News & Press Releases
Mar 10, 2017: DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children
Mar 06, 2017: Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Mar 05, 2017: Data at AAAAI 2017 Show Lasting Response and Favorable Safety Profile of Investigational Agent, Viaskin Peanut, Throughout Three Years of Treatment of Peanut Allergic Children
Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting
Feb 27, 2017: Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Feb 16, 2017: Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
Feb 06, 2017: Selecta Biosciences Presents Preclinical Data Regarding SVP-Enabled Peanut Allergy Therapeutic Vaccine
Feb 01, 2017: Allergy Therapeutics Announces Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine
Dec 20, 2016: Astellas Announces FDA Fast Track Designation for ASP0892, DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions due to Peanut Allergy
Dec 13, 2016: AnaptysBio Announces Clearance of U.S. IND and U.K. CTA for ANB020
Nov 28, 2016: Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
Nov 11, 2016: DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting
Oct 26, 2016: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology
Oct 24, 2016: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut
Oct 03, 2016: AnaptysBio Reports ANB020 Top-Line Phase 1 Clinical Trial Results
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peanut Allergy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Peanut Allergy - Pipeline by Adverum Biotechnologies Inc, H1 2017
Peanut Allergy - Pipeline by Aimmune Therapeutics Inc, H1 2017
Peanut Allergy - Pipeline by Alfacyte Ltd, H1 2017
Peanut Allergy - Pipeline by Allergy Therapeutics Plc, H1 2017
Peanut Allergy - Pipeline by AnaptysBio Inc, H1 2017
Peanut Allergy - Pipeline by ASIT Biotech SA, H1 2017
Peanut Allergy - Pipeline by Astellas Pharma Inc, H1 2017
Peanut Allergy - Pipeline by BioLingus AG, H1 2017
Peanut Allergy - Pipeline by DBV Technologies SA, H1 2017
Peanut Allergy - Pipeline by HAL Allergy BV, H1 2017
Peanut Allergy - Pipeline by Intrommune Therapeutics, H1 2017
Peanut Allergy - Pipeline by Sanofi, H1 2017
Peanut Allergy - Dormant Projects, H1 2017
Peanut Allergy - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Peanut Allergy, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *